Healthcare - Biotechnology - NASDAQ - US
$ 0.4035
-1.59 %
$ 68 M
Market Cap
3.1
P/E
INCOME STATEMENT
0
REVENUE
-108 M
OPERATING INCOME
-101 M
NET INCOME
EFFICIENCY
Earnings Waterfall
X4 Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 2 M |
| Gross Profit | -2 M |
| Operating Expenses | 108 M |
| Operating Income | -108 M |
| Other Expenses | -6.36 M |
| Net Income | -101 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 0 | 0 | 0 | 3.0 | 0 | 3.5 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 2.0 | 2.0 | 1.9 | 0 | 0.7 | 0.1 | 0.2 | 0.3 | 0.4 |
| Gross Profit | (2.0) | (2.0) | (1.9) | 3.0 | (0.7) | 3.4 | (0.2) | (0.3) | (0.4) |
| OPERATING INCOME | |||||||||
| Operating Expenses | 107.5 | 88.1 | 75.3 | 62.9 | 47.8 | 46.2 | 32.3 | 22.0 | 12.7 |
| Selling, General and Administrative Expenses | 35.5 | 27.0 | 24.7 | 20.9 | 17.6 | 18.4 | 8.0 | 6.5 | 2.1 |
| Research and Development Expenses | 72.0 | 61.1 | 50.6 | 41.9 | 30.2 | 31.0 | 28.1 | 17.8 | 12.7 |
| Operating Income | (107.5) | (87.6) | (85.1) | (59.9) | (51.7) | (45.9) | (36.1) | (24.3) | (14.8) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 5.8 | 4.0 | 3.6 | 2.7 | 2.1 | 1.0 | 2.1 | 2.5 | 0.5 |
| Total Other Income | 6.4 | (6.3) | (3.6) | (2.1) | (1.1) | 2.9 | 2.3 | 6.5 | 1.6 |
| Pre-Tax Income | (101.1) | (93.8) | (88.7) | (62.0) | (52.8) | (43.0) | (33.9) | (23.0) | (13.2) |
| NET INCOME | |||||||||
| Tax Provision | 78 K | 28 K | 17 K | 0.1 | 3.8 | 3.9 | 1.9 | 2.6 | 0.4 |
| Net Income | (101.2) | (93.9) | (88.7) | (62.1) | (56.6) | (43.0) | (33.9) | (23.0) | (13.2) |
| EPS | 0.57 | 1.48 | 3.44 | 3.09 | 4.91 | 93.7 | 98.6 | 24.8 | 14.2 |